ARCT 810
Alternative Names: ARCT-810; LUNAR-OTCLatest Information Update: 10 Jul 2025
At a glance
- Originator Arcturus Therapeutics
- Class RNA
- Mechanism of Action Ornithine carbamoyltransferase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 30 Jun 2025 Efficacy data from phase II European trial in Ornithine carbamoyltransferase deficiency disease released by Arcturus Therapeutics
- 30 Jun 2025 Efficacy data from phase II US trial in Ornithine carbamoyltransferase deficiency disease released by Arcturus Therapeutics
- 06 Jan 2025 EMA approves the pediatric investigation plan for Ornithine transcarbamylase deficiency, prior to January 2025